Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) | Not Recruiting
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
CANTOS
Trial Source

Health Conditions
  • Atherosclerosis
Not Recruiting
Recruitment Status
NCT01327846
Primary Trial ID Number
Summary
Main Study (CACZ885M2301) The purpose of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. Sub-study 1 (CACZ885M2301S1) The purpose of this sub-study is to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS). Sub-study 2 (CACZ885M2301S2) The purpose of this CANTOS sub-study is to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care increases insulin secretion and insulin sensitivity.
Primary Outcome Measures
  • Main:Time to first occurrence of major adverse cardiovascular event, which is a composite of CV death, non-fatal MI, and stroke.; 36 months; Substudy 1; Change from baseline in carotid plaque burden in the bifurcation region of the index carotid artery; 36 months; Substudy 2; Change from baseline of the insulin secretion rate (ISR) relative to glucose 0-30 min defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 averaged across the yearly visits.; 36 months
Secondary Outcome Measures
  • Main:Time to first occurrence of the composite cardiovascular endpoint consisting of cardiovascular death, non-fatal MI, stroke and hospitalization for unstable angina requiring unplanned revascularization.; 36 months; Main:Time to new onset type 2 diabetes among patients with pre-diabetes at randomization.; 36 months; Main:Time to first occurrence of non-fatal MI, stroke and all-cause mortality composite.; 36 months; Main: Time to all-cause mortality.; 36 months; Substudy 1; Change from baseline of the total vessel wall area at Month 3 of the index carotid artery.; 36 months; Substudy 1; Mean total vessel wall area across the left and right carotid artery at Month 3 and Month 24.; 36 months; Substudy 1; Change from baseline in corresponding total vessel wall area in the left and right carotid arteries.; 36 months; Substudy 1; The existence of a baseline total vessel wall area by treatment interaction as well as the consistency of the treatment effect across subgroups.; 36 months; Substudy 2; Change from baseline in insulin sensitivity index.; 36 months; Substudy 2; Change from baseline in OGTT stimulated area under curve (AUC) 0-120 min of glucose concentration, insulin concentration, pro-insulin concentration, and insulin concentration/glucose concentration ratio.; 36 months; Substudy 2; Change from baseline in fasting pro-insulin concentration /insulin concentration ratio.; 36 months; Substudy 2; Change from baseline in OGTT stimulated area under the curve (AUC) 0-120 min of C-peptide concentration.; 36 months
Research Question
  • Main Study (CACZ885M2301) The purpose of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. Sub-study 1 (CACZ885M2301S1) The purpose of this sub-study is to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS). Sub-study 2 (CACZ885M2301S2) The purpose of this CANTOS sub-study is to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care increases insulin secretion and insulin sensitivity.
Design Type
Sorry, this information is not available
Ethics Approval
Sorry, this information is not available
Publications
Sorry, this information is not available
Countries of Recruitment
United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; China; Colombia; Croatia; Czech Republic; Ecuador; Estonia; Germany; Greece; Guatemala; Hungary; Iceland; India; Israel; Italy; Japan; Korea, Republic of; Latvia; Lithuania; Mexico; Netherlands; Norway; Peru; Poland; Romania; Russian Federation; Serbia; Slovakia; Slovenia; South Africa; Sweden; Taiwan; Turkey; United Kingdom
Participant Sex
Both
Participant Age Range
18 Years to N/A
Participant Type
Sorry, this information is not available
Trial Sample Size
Sorry, this information is not available
Participant Inclusion Criteria
  • Main Study Inclusion Criteria:
  • - Written informed consent
  • - Male, or Female of non-child-bearing potential
  • - Age ≥ 18 years.
  • - Spontaneous MI at least 30 days before randomization. hsCRP ≥ 2 mg/L
  • Substudy 1 Inclusion:
  • - All Inclusion from Main Study
  • - Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the
  • imaging core laboratory
  • Substudy 2 Inclusion:
  • - All inclusion from Main Study
  • - T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic
  • medication for at least 4 weeks prior to the baseline OGTT test
  • - Willing to have the OGTT assessment started before 10 am
  • Main Study Exclusion Criteria:
  • - Pregnant or nursing (lactating) women
  • - Women of child-bearing potential
  • - Any of the following concomitant diseases
  • - Planned coronary revascularization (PCI or CABG)
  • - Major non-cardiac surgical or endoscopic procedure within past 6 months
  • - Multi-vessel CABG surgery within the past 3 years
  • - Symptomatic patients with Class IV heart failure (HF) (New York Heart Association
  • [NYHA].
  • - Uncontrolled hypertension
  • - Uncontrolled diabetes
  • - History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion
  • - All Main exclusion
  • - Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy
  • - Patients with contraindications to MRI examination (brain aneurysm clip, implanted
  • neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator,
  • prosthetic heart valves, cochlear implant, ocular foreign body or other implanted
  • body, tattoos, implanted insulin pump, metal shrapnel or bullet)
  • - Patients prone to claustrophobia or known anxiety disorders
  • - BMI > 40 kg/m2 Substudy 2 Exclusion
  • - This sub-study does not have any additional exclusion criteria. Other
  • protocol-defined inclusion/exclusion criteria may apply
Participant Exclusion Criteria
  • Main Study Inclusion Criteria:
  • - Written informed consent
  • - Male, or Female of non-child-bearing potential
  • - Age ≥ 18 years.
  • - Spontaneous MI at least 30 days before randomization. hsCRP ≥ 2 mg/L
  • Substudy 1 Inclusion:
  • - All Inclusion from Main Study
  • - Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the
  • imaging core laboratory
  • Substudy 2 Inclusion:
  • - All inclusion from Main Study
  • - T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic
  • medication for at least 4 weeks prior to the baseline OGTT test
  • - Willing to have the OGTT assessment started before 10 am
  • Main Study Exclusion Criteria:
  • - Pregnant or nursing (lactating) women
  • - Women of child-bearing potential
  • - Any of the following concomitant diseases
  • - Planned coronary revascularization (PCI or CABG)
  • - Major non-cardiac surgical or endoscopic procedure within past 6 months
  • - Multi-vessel CABG surgery within the past 3 years
  • - Symptomatic patients with Class IV heart failure (HF) (New York Heart Association
  • [NYHA].
  • - Uncontrolled hypertension
  • - Uncontrolled diabetes
  • - History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion
  • - All Main exclusion
  • - Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy
  • - Patients with contraindications to MRI examination (brain aneurysm clip, implanted
  • neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator,
  • prosthetic heart valves, cochlear implant, ocular foreign body or other implanted
  • body, tattoos, implanted insulin pump, metal shrapnel or bullet)
  • - Patients prone to claustrophobia or known anxiety disorders
  • - BMI > 40 kg/m2 Substudy 2 Exclusion
  • - This sub-study does not have any additional exclusion criteria. Other
  • protocol-defined inclusion/exclusion criteria may apply
Interventions
Drug; Canakinumab; null; [Canakinumab 50 mg, Canakinumab Dose 150 mg, Canakinumab Dose 300 mg]; Drug; Placebo; null; [Placebo]
Design Details
Sorry, this information is not available
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Results Reporting
Sorry, this information is not available
Acronym
CANTOS
Scientific Title
A Randomized, Double-blind, Placebo-controlled, Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients With Elevated hsCRP Including Substudies to Evaluate the Effect of Canakinumab on Carotid Atherosclerosis, and on Glucose Control Following OGTT in T2DM
Secondary Trial Identifying Number
2010-022970-14
Website
Sorry, this information is not available
Study Funded By
Novartis Pharmaceuticals
Funder Type
Sorry, this information is not available
Study Sponsored By
Novartis Pharmaceuticals
Study Also Sponsored By
Sorry, this information is not available
Primary Sponsor Type
Sorry, this information is not available
Secondary Sponsor Type
Sorry, this information is not available
Key Dates

Date of First Enrollment
Date Not Available
Recruitment End Date
Date Not Available
Trial End Date
Date Not Available
Date added to Registry

29 Mar 2011

Last Updated

19 May 2015

Date Record Refreshed on UKCTG

31 Jul 2015